U.S. Drug Spending Will Increase 7.6% in 2015, Including PCSK9 Costs – CMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency expects PCSK9 drugs for cholesterol will have relatively “modest” impact on drug spending across commercial and government payers in 2015, actuaries explain.
You may also be interested in...
US Retail Drug Spending Growth Slowing With No New Sovaldis In Sight
Rate of growth in prescription drug spending is expected to average 6.7% per year from 2016 through 2025, National Health Expenditures report from CMS projects.
Medicare’s Final Coverage Decision On Alzheimer’s Drugs: Thoughts From A Former CMS Chief
Mark McClellan discusses whether CMS’s pending final version of the Medicare national coverage determination on Alzheimer’s drugs might change from the draft and whether the decision should be viewed as a precedent for drugs granted accelerated approvals.
Paxlovid, Molnupiravir Access Threatened By ‘Dismal' Pharmacy Dispensing Fees, CMS Told
Pharmacy organization urges the Centers for Medicare and Medicaid Services to recommend a dispensing fee commensurate with the effort involved in filling scripts for the drugs.